2. Background This drug had not previously been considered by the PBAC.

Save this PDF as:
Size: px
Start display at page:

Download "2. Background This drug had not previously been considered by the PBAC."

Transcription

1 PUBLIC SUMMARY DOCUMENT Product: Ambrisentan, tablets, 5 mg and 10 mg, Volibris Sponsor: GlaxoSmithKline Australia Pty Ltd Date of PBAC Consideration: July Purpose of Application The submission requested a Section 100 (Highly Specialised Drugs) listing for treatment of primary pulmonary hypertension (PPH) or pulmonary arterial hypertension secondary to connective tissue disease (PAH-CTD) in patients with WHO functional class III or IV severity. Highly Specialised Drugs are medicines for the treatment of chronic conditions, which, because of their clinical use or other special features, are restricted to supply to public and private hospitals having access to appropriate specialist facilities. 2. Background This drug had not previously been considered by the PBAC. 3. Registration Status Ambrisentan was TGA registered on 24 November 2008 for the treatment of idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension associated with connective tissue disease in patients with WHO functional class II, III or IV symptoms. 4. Listing Requested and PBAC s View The requested restriction for ambrisentan was similar to the restrictions for bosentan (class III and IV) and sitaxentan (class III), which are the other endothelin receptor antagonists listed on the PBS. For PBAC s views see Recommendation and Reasons. 5. Clinical place for the proposed therapy Ambrisentan would provide an alternative oral therapy for primary pulmonary hypertension and pulmonary arterial hypertension secondary to connective tissue disease, in patients with WHO Function Class III or IV severity. 6. Comparator The submission nominated bosentan as the comparator. 7. Clinical trials The submission presented a placebo based indirect comparison of ambrisentan with bosentan using two randomised ambrisentan placebo controlled 12 week trials (AMB320 and AMB321) and two randomised bosentan placebo controlled 16 week trials (AC351 and AC352). The following table details the trials presented in the submission: Page 1 of 5

2 Trials considered in the submission for the indirect comparison. Trial ID/First Protocol title/publication title Author Common reference placebo Bosentan AC (AC-352) Bosentan therapy for pulmonary arterial hypertension Publication citation Rubin et al (2002). New England Journal of Medicine. 346 (12): AC (AC-351) Ambrisentan AMB 320 (ARIES-1) AMB 321 (ARIES-2) Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: A randomised placebo-controlled study. ARIES-1: A placebo-controlled, efficacy and safety study of ambrisentan in patients with pulmonary arterial hypertension. Ambrisentan therapy for pulmonary arterial hypertension: A comparison by PAH aetiology. AMB-321 (ARIES-2). Ambrisentan in PAH, a phase III, randomised, double-blind, placebocontrolled, multicentre, efficacy study of ambrisentan in subjects with pulmonary arterial hypertension. Channick et al (2001). The Lancet. 358 (9288): Oudiz et al (2006). Chest; 130(4):121S. Badesch DB (2007). Chest, 132 (4):488S ARIES-C Ambrisentan for the treatment of pulmonary arterial hypertension: Results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicentre efficacy (ARIES) study 1 and 2 Galie et al (2008). Circulation,117: PAH = pulmonary arterial hypertension; od = once daily; bd = twice daily; WHO = World Health Organization; FC = functional class The indirect comparison was based on 1) combined ambrisentan data (termed ARIES C in the submission) rather than on the individual ambrisentan trial data (5mg treatment arms were combined as were the placebo arms from AMB321 and AMB320) and pooled bosentan data (125 mg bd) from AC351 (Channick et al (2001) and AC352 (Rubin et al (2002); and 2) sub group data (for WHO class III and IV patients at baseline) given that the ambrisentan trials recruited patients with other WHO functional classes (I-IV) at baseline (40% of patients were WHO class I-II at baseline). The primary outcome was mean change from baseline in 6 minute walk distance (6MWD), which the submission claimed was a valid surrogate for survival. The submission also presented survival data for ambrisentan from ARIES E (an extension study to AMB321 and AMB320) and different bosentan studies (without conducting a formal comparison). 8. Results of trials The submission conducted a placebo based indirect comparison of ambrisentan and bosentan. Page 2 of 5

3 Primary endpoint - the 6 Minute Walk Distance (6MWD) The claim of non-inferiority in the submission was based on two different estimates of the minimal clinically important difference (MCID) in the 6MWD: -35m (based on the power of the ambrisentan trials to detect this difference) and -50m (based on differences observed in the bosentan trials). The results indicated that treatment with either dose of ambrisentan, or with bosentan 125 mg twice daily (bd), is associated with a statistically significant improvement from baseline in 6MWD compared with placebo. There was no statistically significant difference between ambrisentan and bosentan in the placebo based indirect comparison of 6MWD. Secondary endpoints - Borg Dyspnea Index (BDI), change from baseline for WHO functional class and clinical worsening: The placebo based indirect comparisons indicated that there was no statistically significant difference in mean BDI change from baseline between ambrisentan 5 mg daily and bosentan 125mg twice daily, whereas there was a statistically significant difference in mean BDI change from baseline between ambrisentan 10 mg daily and bosentan 125 mg twice daily in favour of ambrisentan. There was no statistically significant difference between ambrisentan (5 mg or 10 mg daily doses) and bosentan 125 mg twice daily dose with respect to improvement in WHO functional class from baseline. The indirect comparison results indicated that there was no statistically significant difference in clinical worsening rates between ambrisentan and bosentan. Haemodynamic data from AMB321/AMB320 were not provided in the submission. With respect to adverse events, the incidence of serious adverse effects (SAEs) was higher for patients treated in the placebo arms compared to patients treated with either dose of ambrisentan. The incidence of any reported serious adverse events was similar for both doses of ambrisentan. With the exception of right ventricular failure for the 5 mg ambrisentan group, no other individual serious adverse event occurred at an incidence greater than 2 %. The most common adverse event in the long term extension ambrisentan study (ARIES E) was peripheral oedema. SAE data for bosentan were predominantly not reported. Abnormal liver function is recognised to be a class effect of endothelin receptor antagonists. The bosentan trials indicated that treatment with the active drug increases the risk of elevated transaminase levels compared to treatment with placebo. Liver function test levels in patients treated with ambrisentan appeared unremarkable throughout the 108 week study period. From the Periodic Safety Update Report for ambrisentan, two new safety issues were identified: fluid retention, requiring intervention with a diuretic or hospitalisation for fluid Page 3 of 5

4 management within weeks of starting ambrisentan therapy, and dyspnoea occurring shortly after initiating ambrisentan therapy. 9. Clinical Claim The submission described the 5 mg daily and 10 mg daily doses of ambrisentan as noninferior in terms of comparative effectiveness and non-inferior in terms of comparative safety over bosentan 125 mg twice daily. 10. Economic Analysis The submission presented a cost minimisation analysis. Ambrisentan 5 mg once daily or ambrisentan 10mg once daily and bosentan 125 mg twice daily were claimed to be equieffective from the placebo-based indirect comparison of ambrisentan to bosentan using two ambrisentan trials (AMB320 and AMB321) and two bosentan trials (AC351 and AC352). 11. Estimated PBS Usage and Financial Implications The submission estimated the likely number of patients/year to be less than 1000 in Year The net financial implications to the PBS were claimed to be nil through all the years of extrapolation (up to 2014). 12. Recommendation and Reasons The PBAC recommended the listing of ambrisentan as a Section 100 Highly Specialised Drugs (HSD) Program Public and Private Hospital Authority required benefit for the treatment of primary pulmonary hypertension (PPH) or pulmonary arterial hypertension secondary to connective tissue disease (PAH-CTD) in patients with a World Health Organisation (WHO) functional class III or IV severity on a cost minimisation basis to bosentan. The equi-effective doses are ambrisentan 5 mg daily and bosentan 125 mg twice daily. The PBAC accepted that bosentan was the appropriate comparator, considering the two drugs belong to the same therapeutic class. The PBAC considered that ambrisentan was non-inferior to bosentan on the basis of the indirect comparison of the mean change from baseline in the six minute walk distance (6MWD) results. The PBAC noted that it would have been informative for haemodynamic data and/ or outcome data to be presented, considering that haemodynamic parameters correlate with clinical state, functional class, exercise capacity, and prognosis in patients with PAH. The PBAC considered the toxicity of ambrisentan appeared non-inferior to bosentan. It was noted that liver function tests in patients treated with ambrisentan appeared to be within acceptable range in the study period, however the PBAC considered that additional time is required to determine whether ambrisentan is associated with liver toxicity as such adverse effects may emerge with longer term treatment. The PBAC considered economic uncertainty remained in the cost effectiveness of ambrisentan, however the uncertainty was similar to that accepted for the other PBS listed endothelin receptor antagonists for the treatment of PPH and PAH. The PBAC noted that the patient population for which listing of ambrisentan was sought are already eligible to receive subsidised treatment with the currently PBS listed PAH therapies and hence that Page 4 of 5

5 ambrisentan will only provide an additional treatment option, with no unique patient group. The PBAC recommended the restriction eligibility and continuation criteria should take account of the TGA approved indications and dosage recommendations for ambrisentan, as should the clinical interchangeability arrangements specified in the PBS restrictions for the agents used in PPH and PAH. The PBAC noted that the Highly Specialised Drugs Working Party support the inclusion of ambrisentan on the HSD Program. Recommendation AMBRISENTAN, tablets, 5 mg and 10 mg Restriction: Section 100 (Highly Specialised Drugs Program) Public and private hospital authority required Complex - to be finalised Pack size: Context for Decision The PBAC helps decide whether and, if so, how medicines should be subsidised in Australia. It considers submissions in this context. A PBAC decision not to recommend listing or not to recommend changing a listing does not represent a final PBAC view about the merits of the medicine. A company can resubmit to the PBAC or seek independent review of the PBAC decision. 14. Sponsor s Comment Page 5 of 5

Product: Tazarotene, cream, 500 micrograms per g (0.05%) and 1.0 mg per g (0.1%), 30 g, Zorac

Product: Tazarotene, cream, 500 micrograms per g (0.05%) and 1.0 mg per g (0.1%), 30 g, Zorac PUBLIC SUMMARY DOCUMENT Product: Tazarotene, cream, 500 micrograms per g (0.05%) and 1.0 mg per g (0.1%), 30 g, Zorac Sponsor: Genepharm Australasia Ltd Date of PBAC Consideration: July 2007 1. Purpose

More information

Riociguat Clinical Trial Program

Riociguat Clinical Trial Program Riociguat Clinical Trial Program Riociguat (BAY 63-2521) is an oral agent being investigated as a new approach to treat chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension

More information

2. Background This indication of rivaroxaban had not previously been considered by the PBAC.

2. Background This indication of rivaroxaban had not previously been considered by the PBAC. PUBLIC SUMMARY DOCUMENT Product: Rivaroxaban, tablets, 15mg and 20mg, Xarelto Sponsor: Bayer Australia Ltd Date of PBAC Consideration: March 2013 1. Purpose of Application The application requested the

More information

Scottish Medicines Consortium

Scottish Medicines Consortium Scottish Medicines Consortium sildenafil citrate 20mg tablets (Revatio ) No. (235/06) Pfizer New indication 6 January 2006 The Scottish Medicines Consortium (SMC) has completed its assessment of the above

More information

The submission positioned dimethyl fumarate as a first-line treatment option.

The submission positioned dimethyl fumarate as a first-line treatment option. Product: Dimethyl Fumarate, capsules, 120 mg and 240 mg, Tecfidera Sponsor: Biogen Idec Australia Pty Ltd Date of PBAC Consideration: July 2013 1. Purpose of Application The major submission sought an

More information

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health Technology Appraisal. Drugs for the treatment of pulmonary arterial hypertension

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health Technology Appraisal. Drugs for the treatment of pulmonary arterial hypertension NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Health Technology Appraisal Drugs for the treatment of Remit / Appraisal objective: Final scope To appraise the clinical and cost effectiveness of

More information

2. Background This was the fourth submission for everolimus requesting listing for clear cell renal carcinoma.

2. Background This was the fourth submission for everolimus requesting listing for clear cell renal carcinoma. PUBLIC SUMMARY DOCUMENT Product: Everolimus, tablets, 5 mg and 10 mg, Afinitor Sponsor: Novartis Pharmaceuticals Australia Pty Ltd Date of PBAC Consideration: November 2011 1. Purpose of Application To

More information

Clinical Commissioning Policy: Targeted Therapies for Pulmonary Hypertension Functional Class II. April 2013. Reference : NHSCB/A11/P/a

Clinical Commissioning Policy: Targeted Therapies for Pulmonary Hypertension Functional Class II. April 2013. Reference : NHSCB/A11/P/a Clinical Commissioning Policy: Targeted Therapies for Pulmonary Hypertension Functional Class II April 2013 Reference : NHS Commissioning Board Clinical Commissioning Policy: Amendment to National Policy

More information

FREEDOM C: A 16-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Comparison of the Efficacy and Safety of Oral UT-15C

FREEDOM C: A 16-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Comparison of the Efficacy and Safety of Oral UT-15C FREEDOM C: A 16-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Comparison of the Efficacy and Safety of Oral UT-15C SR in Combination with an ERA and/or a PDE-5 Inhibitor

More information

CADTH CANADIAN DRUG EXPERT REVIEW COMMITTEE FINAL RECOMMENDATION

CADTH CANADIAN DRUG EXPERT REVIEW COMMITTEE FINAL RECOMMENDATION CADTH CANADIAN DRUG EXPERT REVIEW COMMITTEE FINAL RECOMMENDATION RIOCIGUAT (Adempas Bayer HealthCare Inc.) Indication: Pulmonary Arterial Hypertension Recommendation: The CADTH Canadian Drug Expert Review

More information

Target therapies for the treatment of pulmonary arterial hypertension in Adults

Target therapies for the treatment of pulmonary arterial hypertension in Adults Paper K2 National Specialised Commissioning Group Commissioning Policy Target therapies for the treatment of pulmonary arterial hypertension in Adults POLICY PUBLISHED: 1 JULY 2008 POLICY REVISED: 14 JANUARY

More information

Summary Review for Regulatory Action

Summary Review for Regulatory Action Summary Review for Regulatory Action Date (electronic stamp) From Norman Stockbridge Subject Division Director Summary Review NDA/BLA # Supplement # NDA 21-290 Applicant Name Actelion Date of Submission

More information

Pulmonary Artery Hypertension

Pulmonary Artery Hypertension Pulmonary Artery Hypertension Janet M. Pinson, RN, MSN, ACNP Maureen P. Flattery, RN, MS, ANP Virginia Commonwealth University Health System Richmond, VA Pulmonary artery hypertension (PAH) is defined

More information

CADTH Therapeutic Review Report

CADTH Therapeutic Review Report Canadian Agency for Drugs and Technologies in Health Agence canadienne des médicaments et des technologies de la santé CADTH Therapeutic Review Report March 2015 Drugs for Pulmonary Arterial Hypertension:

More information

Evidence briefing on drug treatments for functional class II pulmonary hypertension

Evidence briefing on drug treatments for functional class II pulmonary hypertension Evidence briefing on drug treatments for functional class II pulmonary hypertension The North of England Specialised Commissioning Group is the lead organisation charged with commissioning targeted therapies

More information

Version History. Previous Versions. Drugs for MS.Drug facts box fingolimod Version 1.0 Author

Version History. Previous Versions. Drugs for MS.Drug facts box fingolimod Version 1.0 Author Version History Policy Title Drugs for MS.Drug facts box fingolimod Version 1.0 Author West Midlands Commissioning Support Unit Publication Date Jan 2013 Review Date Supersedes/New (Further fields as required

More information

Medical management of CHF: A New Class of Medication. Al Timothy, M.D. Cardiovascular Institute of the South

Medical management of CHF: A New Class of Medication. Al Timothy, M.D. Cardiovascular Institute of the South Medical management of CHF: A New Class of Medication Al Timothy, M.D. Cardiovascular Institute of the South Disclosures Speakers Bureau for Amgen Background Chronic systolic congestive heart failure remains

More information

Version History. Previous Versions. Drugs for MS.Drug facts box fampridine Version 1.0 Author

Version History. Previous Versions. Drugs for MS.Drug facts box fampridine Version 1.0 Author Version History Policy Title Drugs for MS.Drug facts box fampridine Version 1.0 Author West Midlands Commissioning Support Unit Publication Date Jan 2013 Review Date Supersedes/New (Further fields as required

More information

The Global Alliance against Chronic Respiratory Diseases

The Global Alliance against Chronic Respiratory Diseases The Global Alliance against Chronic Respiratory Diseases Pulmonary hypertension Dr Marc Humbert What is the burden of pulmonary hypertension? The true burden of pulmonary hypertension is currently unknown

More information

OVERVIEW FDA-APPROVED INDICATIONS

OVERVIEW FDA-APPROVED INDICATIONS Tufts Health Together Tufts Health Direct Pharmacy Medical Necessity Guidelines Pulmonary Hypertension Effective: December 9, 2014 Clinical documentation and prior authorization required Not covered Pharmacy

More information

Drugs for MS.Drug fact box cannabis extract (Sativex) Version 1.0 Author

Drugs for MS.Drug fact box cannabis extract (Sativex) Version 1.0 Author Version History Policy Title Drugs for MS.Drug fact box cannabis extract (Sativex) Version 1.0 Author West Midlands Commissioning Support Unit Publication Date Jan 2013 Review Date Supersedes/New (Further

More information

1. Phosphodiesterase Type 5 Enzyme Inhibitors: Sildenafil (Revatio), Tadalafil (Adcirca)

1. Phosphodiesterase Type 5 Enzyme Inhibitors: Sildenafil (Revatio), Tadalafil (Adcirca) This policy has been developed through review of medical literature, consideration of medical necessity, generally accepted medical practice standards, and approved by the IEHP Pharmacy and Therapeutic

More information

Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism ERRATUM

Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism ERRATUM Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism ERRATUM This report was commissioned by the NIHR HTA Programme as project number 12/78

More information

Idiopathic Pulmonary Fibrosis (IPF) Research

Idiopathic Pulmonary Fibrosis (IPF) Research Idiopathic Pulmonary Fibrosis (IPF): Why Early Referral is Critical Even if Your Patient is Not Eligible for a Clinical Trial Idiopathic Pulmonary Fibrosis (IPF) Research Management of IPF requires a confident

More information

Pharmacy Medical Necessity Guidelines: Pulmonary Hypertension Medications

Pharmacy Medical Necessity Guidelines: Pulmonary Hypertension Medications Pharmacy Medical Necessity Guidelines: Pulmonary Hypertension Medications Effective: January 1, 2016 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review

More information

Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism

Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary Issued: July 2012 guidance.nice.org.uk/ta NHS Evidence has accredited the process used

More information

A Review of Sitaxsentan Sodium in Patients with Pulmonary Arterial Hypertension

A Review of Sitaxsentan Sodium in Patients with Pulmonary Arterial Hypertension A Review of Sitaxsentan Sodium in Patients with Pulmonary Arterial Hypertension The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters.

More information

Recently approved drugs offer significant improvements for treatment options in pulmonary arterial hypertension

Recently approved drugs offer significant improvements for treatment options in pulmonary arterial hypertension DISEASE MANAGEMENT Recently approved drugs offer significant improvements for treatment options in pulmonary arterial hypertension Treatment of pulmonary arterial hypertension (PAH) Class I. PAH without

More information

PAH. Salman Bin AbdulAziz University College Of Pharmacy 22/01/35

PAH. Salman Bin AbdulAziz University College Of Pharmacy 22/01/35 Salman Bin AbdulAziz University College Of Pharmacy PAH Therapeutics II PHCL 430 Ahmed A AlAmer PharmD R.W. is a 38-year-old obese woman who presents with increasing symptoms of fatigue and shortness of

More information

Sponsor Novartis Pharmaceuticals

Sponsor Novartis Pharmaceuticals Clinical Trial Results Database Page 1 Sponsor Novartis Pharmaceuticals Generic Drug Name Indacaterol Therapeutic Area of Trial Chronic Obstructive Pulmonary Disease (COPD) Indication studied: COPD Study

More information

Cancer Treatments Subcommittee of PTAC Meeting held 18 September 2015. (minutes for web publishing)

Cancer Treatments Subcommittee of PTAC Meeting held 18 September 2015. (minutes for web publishing) Cancer Treatments Subcommittee of PTAC Meeting held 18 September 2015 (minutes for web publishing) Cancer Treatments Subcommittee minutes are published in accordance with the Terms of Reference for the

More information

Subject: No. Page PROTOCOL AND CASE REPORT FORM DEVELOPMENT AND REVIEW Standard Operating Procedure

Subject: No. Page PROTOCOL AND CASE REPORT FORM DEVELOPMENT AND REVIEW Standard Operating Procedure 703 1 of 11 POLICY The Beaumont Research Coordinating Center (BRCC) will provide advice to clinical trial investigators on protocol development, content and format. Upon request, the BRCC will review a

More information

PROTOCOL SYNOPSIS Evaluation of long-term opioid efficacy for chronic pain

PROTOCOL SYNOPSIS Evaluation of long-term opioid efficacy for chronic pain P a g e 1 PROTOCOL SYNOPSIS Evaluation of long-term opioid efficacy for chronic pain Clinical Phase 4 Study Centers Study Period 25 U.S. sites identified and reviewed by the Steering Committee and Contract

More information

Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism

Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary Issued: July 2012 guidance.nice.org.uk/ta NICE has accredited the process used by the

More information

Version History. Previous Versions. for secondary progressive MS (SPMS) Policy Title. Drugs for MS.Drug facts box Interferon beta 1b

Version History. Previous Versions. for secondary progressive MS (SPMS) Policy Title. Drugs for MS.Drug facts box Interferon beta 1b Version History Policy Title Drugs for MS.Drug facts box Interferon beta 1b for secondary progressive MS (SPMS) Version 1.0 Author West Midlands Commissioning Support Unit Publication Date Jan 2013 Review

More information

Version History. Previous Versions. Policy Title. Drugs for MS.Drug facts box Glatiramer Acetate Version 1.0 Author

Version History. Previous Versions. Policy Title. Drugs for MS.Drug facts box Glatiramer Acetate Version 1.0 Author Version History Policy Title Drugs for MS.Drug facts box Glatiramer Acetate Version 1.0 Author West Midlands Commissioning Support Unit Publication Date Jan 2013 Review Date Supersedes/New (Further fields

More information

Cost-effectiveness of Pirfenidone (Esbriet ) for the treatment of Idiopathic Pulmonary Fibrosis.

Cost-effectiveness of Pirfenidone (Esbriet ) for the treatment of Idiopathic Pulmonary Fibrosis. Cost-effectiveness of Pirfenidone (Esbriet ) for the treatment of Idiopathic Pulmonary Fibrosis. March 2013 1. Pirfenidone is indicated in adults for the treatment of mild to moderate Idiopathic Pulmonary

More information

COMMITTEE FOR HUMAN MEDICINAL PRODUCTS (CHMP) DRAFT GUIDELINE ON THE EVALUATION OF MEDICINAL PRODUCTS FOR CARDIOVASCULAR DISEASE PREVENTION

COMMITTEE FOR HUMAN MEDICINAL PRODUCTS (CHMP) DRAFT GUIDELINE ON THE EVALUATION OF MEDICINAL PRODUCTS FOR CARDIOVASCULAR DISEASE PREVENTION European Medicines Agency London, 19 July 2007 Doc. Ref. EMEA/CHMP/EWP/311890/2007 COMMITTEE FOR HUMAN MEDICINAL PRODUCTS (CHMP) DRAFT GUIDELINE ON THE EVALUATION OF MEDICINAL PRODUCTS FOR CARDIOVASCULAR

More information

Adoption by CHMP for release for consultation November 2010. End of consultation (deadline for comments) 31 March 2011

Adoption by CHMP for release for consultation November 2010. End of consultation (deadline for comments) 31 March 2011 1 2 3 November 2010 EMA/759784/2010 Committee for Medicinal Products for Human Use 4 5 6 7 Reflection paper on the need for active control in therapeutic areas where use of placebo is deemed ethical and

More information

Rivaroxaban for acute coronary syndromes

Rivaroxaban for acute coronary syndromes Northern Treatment Advisory Group Rivaroxaban for acute coronary syndromes Lead author: Nancy Kane Regional Drug & Therapeutics Centre (Newcastle) May 2014 2014 Summary Current long-term management following

More information

Effect of liraglutide on body weight in overweight or obese subjects with type 2 diabetes: SCALE - Diabetes

Effect of liraglutide on body weight in overweight or obese subjects with type 2 diabetes: SCALE - Diabetes Effect of liraglutide on body weight in overweight or obese subjects with type 2 diabetes: SCALE - Diabetes This trial is conducted in Africa, Asia, Europe and the United States of America (USA). The aim

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical

More information

Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation

Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation Issued: May 2012 guidance.nice.org.uk/ta256 NICE has accredited the process used by the Centre for Health

More information

Meta-Analysis of Randomized Controlled Trials on Treatment of Pulmonary Arterial Hypertension

Meta-Analysis of Randomized Controlled Trials on Treatment of Pulmonary Arterial Hypertension Circulation Journal Official Journal of the Japanese Circulation Society http://www.j-circ.or.jp Meta-Analysis of Randomized Controlled Trials on Treatment of Pulmonary Arterial Hypertension Bing He, BSc;

More information

Harmony Clinical Trial Medical Media Factsheet

Harmony Clinical Trial Medical Media Factsheet Overview Harmony is the global Phase III clinical trial program for Tanzeum (albiglutide), a product developed by GSK for the treatment of type 2 diabetes. The comprehensive program comprised eight individual

More information

ELIGIBILITY CRITERIA FOR PULMONARY ARTERIAL HYPERTENSION THERAPY

ELIGIBILITY CRITERIA FOR PULMONARY ARTERIAL HYPERTENSION THERAPY ELIGIBILITY CRITERIA FOR PULMONARY ARTERIAL HYPERTENSION THERAPY Contents ELIGIBILITY CRITERIA FOR INITIATION OF PULMONARY ARTERIAL HYPERTENSION THERAPY... 2 Initial Application for Funding of Pulmonary

More information

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON THE EVALUATION OF MEDICINAL PRODUCTS FOR CARDIOVASCULAR DISEASE PREVENTION

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON THE EVALUATION OF MEDICINAL PRODUCTS FOR CARDIOVASCULAR DISEASE PREVENTION European Medicines Agency Pre-Authorisation Evaluation of Medicines for Human Use London, 25 September 2008 Doc. Ref. EMEA/CHMP/EWP/311890/2007 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE

More information

Missing Data Sensitivity Analysis of a Continuous Endpoint An Example from a Recent Submission

Missing Data Sensitivity Analysis of a Continuous Endpoint An Example from a Recent Submission Missing Data Sensitivity Analysis of a Continuous Endpoint An Example from a Recent Submission Arno Fritsch Clinical Statistics Europe, Bayer November 21, 2014 ASA NJ Chapter / Bayer Workshop, Whippany

More information

Sponsor. Novartis Generic Drug Name. Vildagliptin. Therapeutic Area of Trial. Type 2 diabetes. Approved Indication. Investigational.

Sponsor. Novartis Generic Drug Name. Vildagliptin. Therapeutic Area of Trial. Type 2 diabetes. Approved Indication. Investigational. Clinical Trial Results Database Page 1 Sponsor Novartis Generic Drug Name Vildagliptin Therapeutic Area of Trial Type 2 diabetes Approved Indication Investigational Study Number CLAF237A2386 Title A single-center,

More information

TUTORIAL on ICH E9 and Other Statistical Regulatory Guidance. Session 1: ICH E9 and E10. PSI Conference, May 2011

TUTORIAL on ICH E9 and Other Statistical Regulatory Guidance. Session 1: ICH E9 and E10. PSI Conference, May 2011 TUTORIAL on ICH E9 and Other Statistical Regulatory Guidance Session 1: PSI Conference, May 2011 Kerry Gordon, Quintiles 1 E9, and how to locate it 2 ICH E9 Statistical Principles for Clinical Trials (Issued

More information

Pharmacy Policy Bulletin

Pharmacy Policy Bulletin Pharmacy Policy Bulletin Title: Policy #: Pulmonary Arterial Hypertensive (PAH) agents Rx.01.83 Application of pharmacy policy is determined by benefits and contracts. Benefits may vary based on product

More information

Acknowledgements. PAH in Children: Natural History. The Sildenafil Saga

Acknowledgements. PAH in Children: Natural History. The Sildenafil Saga The Sildenafil Saga David L. Wessel, MD Executive Vice President Chief Medical Officer Ikaria Distinguished Professor of Critical Care Children s National Medical Center Washington, DC, USA Acknowledgements

More information

ABOUT XARELTO CLINICAL STUDIES

ABOUT XARELTO CLINICAL STUDIES ABOUT XARELTO CLINICAL STUDIES FAST FACTS Xarelto (rivaroxaban) is a novel, oral direct Factor Xa inhibitor. On September 30, 2008, the European Commission granted marketing approval for Xarelto for the

More information

Clinical Study Synopsis

Clinical Study Synopsis Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace

More information

boceprevir 200mg capsule (Victrelis ) Treatment experienced patients SMC No. (722/11) Merck, Sharpe and Dohme Ltd

boceprevir 200mg capsule (Victrelis ) Treatment experienced patients SMC No. (722/11) Merck, Sharpe and Dohme Ltd boceprevir 200mg capsule (Victrelis ) Treatment experienced patients SMC No. (722/11) Merck, Sharpe and Dohme Ltd 09 September 2011 The Scottish Medicines Consortium (SMC) has completed its assessment

More information

PULMONARY ARTERIAL HYPERTENSION AGENTS

PULMONARY ARTERIAL HYPERTENSION AGENTS Approvable Criteria: PULMONARY ARTERIAL HYPERTENSION AGENTS Brand Name Generic Name Length of Authorization Revatio Sildenafil citrate Calendar Year Adcirca Tadalafil Calendar Year Letairis Ambrisentan

More information

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Tracleer 62.5 mg film-coated tablets Tracleer 125 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Tracleer

More information

Tomas Pulido, Carla Murillo, Paulina Ramírez-Neria, Viridiana Hurtado, Paola de la Garza, Sandra Astorga, María Teresa Miranda and Julio Sandoval

Tomas Pulido, Carla Murillo, Paulina Ramírez-Neria, Viridiana Hurtado, Paola de la Garza, Sandra Astorga, María Teresa Miranda and Julio Sandoval Clinical Medicine Insights: Therapeutics Review Open Access Full open access to this and thousands of other papers at http://www.la-press.com. Management of Pulmonary Arterial Hypertension with Sitaxentan

More information

Pulmonary arterial hypertension (PAH) is a

Pulmonary arterial hypertension (PAH) is a Eur Respir Rev 2010; 19: 118, 279 287 DOI: 10.1183/09059180.00008010 CopyrightßERS 2010 REVIEW Management of severe pulmonary arterial hypertension J-L. Vachiéry* and G. Simonneau # ABSTRACT: Pulmonary

More information

Everolimus plus exemestane for second-line endocrine treatment of oestrogen receptor positive metastatic breast cancer

Everolimus plus exemestane for second-line endocrine treatment of oestrogen receptor positive metastatic breast cancer LONDON CANCER NEWS DRUGS GROUP RAPID REVIEW Everolimus plus exemestane for second-line endocrine treatment of oestrogen receptor positive metastatic breast cancer Everolimus plus exemestane for second-line

More information

Prior Authorization Guideline

Prior Authorization Guideline Prior Authorization Guideline Guideline: CSD - Suboxone Therapeutic Class: Central Nervous System Agents Therapeutic Sub-Class: Analgesics and Antipyretics (Opiate Partial Agonists) Client: County of San

More information

TEMPLATE DATA MANAGEMENT PLAN

TEMPLATE DATA MANAGEMENT PLAN TEMPLATE DATA MANAGEMENT PLAN ICRIN (QM sub group) Version: XX Date: XXXXXXX Page 1 of 6 1.0 Document Ownership The Data Management Plan (DMP) will be initiated and subsequently owned by the Data Manager

More information

Guidance on Investigational Medicinal Products (IMPs) and other medicinal products used in Clinical Trials

Guidance on Investigational Medicinal Products (IMPs) and other medicinal products used in Clinical Trials EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL Consumer goods Pharmaceuticals Guidance on Investigational Medicinal Products (IMPs) and other medicinal products used in Clinical Trials

More information

*Documentation of pretreatment results from right heart catheterization and PEA required, as applicable

*Documentation of pretreatment results from right heart catheterization and PEA required, as applicable DRUG POLICY BENEFIT APPLICATION Pulmonary Arterial Hypertension Benefit determinations are based on the applicable contract language in effect at the time the services were rendered. Exclusions, limitations

More information

Summary 1. Comparative-effectiveness

Summary 1. Comparative-effectiveness Cost-effectiveness of Delta-9-tetrahydrocannabinol/cannabidiol (Sativex ) as add-on treatment, for symptom improvement in patients with moderate to severe spasticity due to MS who have not responded adequately

More information

Cost-effectiveness of dimethyl fumarate (Tecfidera ) for the treatment of adult patients with relapsing remitting multiple sclerosis

Cost-effectiveness of dimethyl fumarate (Tecfidera ) for the treatment of adult patients with relapsing remitting multiple sclerosis Cost-effectiveness of dimethyl fumarate (Tecfidera ) for the treatment of adult patients with relapsing remitting multiple sclerosis The NCPE has issued a recommendation regarding the cost-effectiveness

More information

Articles Presented. Journal Presentation. Dr Albert Lo. Dr Albert Lo

Articles Presented. Journal Presentation. Dr Albert Lo. Dr Albert Lo * This presentation is prepared by the author in one s personal capacity for the purpose of academic exchange and does not represent the views of his/her organisations on the topic discussed. Journal Presentation

More information

Nalmefene for reducing alcohol consumption in people with alcohol dependence

Nalmefene for reducing alcohol consumption in people with alcohol dependence Nalmefene for reducing alcohol consumption in people with alcohol dependence Issued: November 2014 guidance.nice.org.uk/ta325 NICE has accredited the process used by the Centre for Health Technology Evaluation

More information

Requirements for Drug Information Centres

Requirements for Drug Information Centres FIP Pharmacy Information Section Requirements for Drug Information Centres Summary All countries should provide drug information services either independently or as part of a regional network. The service

More information

PULMONARY HYPERTENSION. Charles A. Thompson, M.D., FACC, FSCAI Cardiovascular Institute of the South Zachary, Louisiana

PULMONARY HYPERTENSION. Charles A. Thompson, M.D., FACC, FSCAI Cardiovascular Institute of the South Zachary, Louisiana PULMONARY HYPERTENSION Charles A. Thompson, M.D., FACC, FSCAI Cardiovascular Institute of the South Zachary, Louisiana What is Pulmonary Hypertension? What is normal? Pulmonary artery systolic pressure

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Cancer Drug and Biological Products Clinical Data in Marketing Applications U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and

More information

Oral Zinc Supplementation as an Adjunct Therapy in the Management of Hepatic Encephalopathy: A Randomized Controlled Trial

Oral Zinc Supplementation as an Adjunct Therapy in the Management of Hepatic Encephalopathy: A Randomized Controlled Trial Oral Zinc Supplementation as an Adjunct Therapy in the Management of Hepatic Encephalopathy: A Randomized Controlled Trial Marcus R. Pereira A. Study Purpose Hepatic encephalopathy is a common complication

More information

PG Certificate / PG Diploma / MSc in Clinical Pharmacy

PG Certificate / PG Diploma / MSc in Clinical Pharmacy PG Certificate / PG Diploma / MSc in Clinical Pharmacy Programme Information September 2014 Entry School of Pharmacy Queen s University Belfast Queen s University Belfast - Clinical Pharmacy programme

More information

Medication Policy Manual. Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012

Medication Policy Manual. Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012 Medication Policy Manual Policy No: dru283 Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012 Committee Approval Date: December 12, 2014 Next Review Date: December 2015 Effective Date: January

More information

Biotie Therapies Oyj Biotie Therapies Corp. Varsinainen yhtiökokous 26.5.2015 Annual General Meeting 26 May 2015

Biotie Therapies Oyj Biotie Therapies Corp. Varsinainen yhtiökokous 26.5.2015 Annual General Meeting 26 May 2015 Biotie Therapies Oyj Biotie Therapies Corp. Varsinainen yhtiökokous 26.5.2015 Annual General Meeting 26 May 2015 1 Timo Veromaa President & CEO 2 Company Highlights 2014 through Q1 2015 Continued advances

More information

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE. Current Step 4 version

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE. Current Step 4 version INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE THE EXTENT OF POPULATION EXPOSURE TO ASSESS CLINICAL

More information

Guidance for Industry Diabetes Mellitus Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes

Guidance for Industry Diabetes Mellitus Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes Guidance for Industry Diabetes Mellitus Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes U.S. Department of Health and Human Services Food and Drug Administration Center

More information

Position Statement from the Irish Thoracic Society on the treatment of Idiopathic Pulmonary Fibrosis

Position Statement from the Irish Thoracic Society on the treatment of Idiopathic Pulmonary Fibrosis BACKGROUND Position Statement from the Irish Thoracic Society on the treatment of Idiopathic Pulmonary Fibrosis Idiopathic Pulmonary Fibrosis (IPF) is a rare, chronic and fatal disease characterised by

More information

GENERAL CONSIDERATIONS FOR CLINICAL TRIALS E8

GENERAL CONSIDERATIONS FOR CLINICAL TRIALS E8 INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE GENERAL CONSIDERATIONS FOR CLINICAL TRIALS E8 Current

More information

Developing Innovative Therapeutics for People with Orphan Liver Disease

Developing Innovative Therapeutics for People with Orphan Liver Disease Developing Innovative Therapeutics for People with Orphan Liver Disease PIPELINE PROGRESS AND FIRST QUARTER 2015 EARNINGS UPDATE NASDAQ: OCRX Forward-Looking Statements Certain statements in this presentation

More information

Therapeutic Class Overview Pulmonary Arterial Hypertension Agents

Therapeutic Class Overview Pulmonary Arterial Hypertension Agents Therapeutic Class Overview Pulmonary Arterial Hypertension Agents Therapeutic Class Overview/Summary: The oral pulmonary hypertension agents are Food Drug Administration (FDA)-approved for the treatment

More information

Incidence of drug related problems

Incidence of drug related problems Incidence of drug related problems Birthe Søndergaard Associate Professor. Faculty of Pharmaceutical Sciences. University of Copenhagen Disposition Drug related problems definition and classifications

More information

A Guide to Clinical Trials

A Guide to Clinical Trials A Guide to Clinical Trials For young people with cancer and their parents Children s Cancer and Leukaemia Group www.cclg.org.uk Original booklet produced in conjunction with the CCLG Patient Advocacy Committee.

More information

Which injectable medication should I take for relapsing-remitting multiple sclerosis?

Which injectable medication should I take for relapsing-remitting multiple sclerosis? Which injectable medication should I take for relapsing-remitting multiple sclerosis? A decision aid to discuss options with your doctor This decision aid is for you if you: Have multiple sclerosis Have

More information

Summary of the risk management plan (RMP) for Rasagiline ratiopharm (rasagiline)

Summary of the risk management plan (RMP) for Rasagiline ratiopharm (rasagiline) EMA/744222/2014 Summary of the risk management plan (RMP) for Rasagiline ratiopharm (rasagiline) This is a summary of the risk management plan (RMP) for Rasagiline ratiopharm, which details the measures

More information

Medication Policy Manual. Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012

Medication Policy Manual. Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012 Medication Policy Manual Policy No: dru283 Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012 Committee Approval Date: December 11, 2015 Next Review Date: December 2016 Effective Date: January

More information

Sponsor Novartis. Generic Drug Name Secukinumab. Therapeutic Area of Trial Psoriasis. Approved Indication investigational

Sponsor Novartis. Generic Drug Name Secukinumab. Therapeutic Area of Trial Psoriasis. Approved Indication investigational Clinical Trial Results Database Page 2 Sponsor Novartis Generic Drug Name Secukinumab Therapeutic Area of Trial Psoriasis Approved Indication investigational Clinical Trial Results Database Page 3 Study

More information

Elements for a Public Summary

Elements for a Public Summary VI.2 Elements for a Public Summary VI.2.1 Overview of Disease Epidemiology Hunter syndrome is a rare genetic disease which mainly affects males of all ethnicities. The incidence rate ranges from 0.6 to

More information

RATE VERSUS RHYTHM CONTROL OF ATRIAL FIBRILLATION: SPECIAL CONSIDERATION IN ELDERLY. Charles Jazra

RATE VERSUS RHYTHM CONTROL OF ATRIAL FIBRILLATION: SPECIAL CONSIDERATION IN ELDERLY. Charles Jazra RATE VERSUS RHYTHM CONTROL OF ATRIAL FIBRILLATION: SPECIAL CONSIDERATION IN ELDERLY Charles Jazra NO CONFLICT OF INTEREST TO DECLARE Relationship Between Atrial Fibrillation and Age Prevalence, percent

More information

ESCMID Online Lecture Library. by author

ESCMID Online Lecture Library. by author Do statins improve outcomes of patients with sepsis and pneumonia? Jordi Carratalà Department of Infectious Diseases Statins for sepsis & community-acquired pneumonia Sepsis and CAP are major healthcare

More information

Journal Club: Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy by the AIM-HIGH Investigators

Journal Club: Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy by the AIM-HIGH Investigators Journal Club: Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy by the AIM-HIGH Investigators Shaikha Al Naimi Doctor of Pharmacy Student College of Pharmacy Qatar University

More information

Teriflunomide for treating relapsing remitting multiple sclerosis

Teriflunomide for treating relapsing remitting multiple sclerosis Teriflunomide for treating relapsing remitting multiple Issued: January 2014 last modified: June 2014 guidance.nice.org.uk/ta NICE has accredited the process used by the Centre for Health Technology Evaluation

More information

Description of problem Description of proposed amendment Justification for amendment ERG response

Description of problem Description of proposed amendment Justification for amendment ERG response KEY INACCURACIES Issue 1 Distinguishing between groups of STEMI patients Key issue throughout the report The ERG distinguishes between groups of STEMI patients defining four patient groups: STEMI without

More information

boceprevir 200mg capsule (Victrelis ) Treatment naïve patients SMC No. (723/11) Merck Sharpe and Dohme Ltd

boceprevir 200mg capsule (Victrelis ) Treatment naïve patients SMC No. (723/11) Merck Sharpe and Dohme Ltd boceprevir 200mg capsule (Victrelis ) Treatment naïve patients SMC No. (723/11) Merck Sharpe and Dohme Ltd 09 September 2011 The Scottish Medicines Consortium (SMC) has completed its assessment of the

More information

Cost-effectiveness of teriflunomide (Aubagio ) for the treatment of adult patients with relapsing remitting multiple sclerosis

Cost-effectiveness of teriflunomide (Aubagio ) for the treatment of adult patients with relapsing remitting multiple sclerosis Cost-effectiveness of teriflunomide (Aubagio ) for the treatment of adult patients with relapsing remitting multiple sclerosis The NCPE has issued a recommendation regarding the cost-effectiveness of teriflunomide

More information

Supplementary webappendix

Supplementary webappendix Supplementary webappendix This webappendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Giovannoni G, Gold R, Selmaj K, et al,

More information

Bios 6648: Design & conduct of clinical research

Bios 6648: Design & conduct of clinical research Bios 6648: Design & conduct of clinical research Section 1 - Specifying the study setting and objectives 1. Specifying the study setting and objectives 1.0 Background Where will we end up?: (a) The treatment

More information

Addendum to Clinical Review for NDA 22-512

Addendum to Clinical Review for NDA 22-512 Addendum to Clinical Review for DA 22-512 Drug: Sponsor: Indication: Division: Reviewers: dabigatran (Pradaxa) Boehringer Ingelheim Prevention of stroke and systemic embolism in atrial fibrillation Division

More information